Kamada - High Quality Pharmaceuticals - Kamada Pharmaceuticals

EACH LIFE IS UNIQUE

Kamada is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities.

Latest Updates

Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years

Dec. 6, 2023

Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance

Nov. 13, 2023

Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023

Nov. 8, 2023

Kamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data

Oct. 16, 2023

Kamada Provides Corporate Update on its Israel Operations

Oct. 10, 2023

Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance

Aug. 16, 2023

UPCOMING EVENT
Kamada to exhibit at the annual American Transplantation Conference ( ATC )
Jun. 3 - 7, 2023
San Diego
UPDATED COMPANY PRESENTATION

PRODUCTS

Our proprietary platform technology and know-how allow us to extract and purify protein therapeutics from human plasma.

OUR
PRODUCTS

PIPELINE

Kamada’s Inhaled AAT has the potential of becoming a transformational next- generation augmentation therapy for Alpha-1 Antitrypsin Deficiency patients.

ALPHA-1 ANTITRYPSIN MECHANISM OF ACTION

The unique properties and demonstrated clinical safety of AAT, render it an attractive therapeutic candidate for various medical conditions.

This video illustrates the mechanism of action of AAT, and its possible therapeutic effects.

Committed to Alpha-1 Patients

Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults. It is associated with an increased risk of developing pulmonary emphysema and liver disease, and also skin problems (panniculitis) and vasculitis.
Supporting prevention of CMV disease after solid organ transplantation

Cytomegalovirus (CMV) is a common virus for people of all ages. It belongs to the Herpesviridae family and is highly evolved and adapted to humans.
MORE
THERAPEUTIC
FOCUS
AREAS

Latest Updates

UPCOMING EVENT

UPDATED COMPANY PRESENTATION

PRODUCTS

PIPELINE

ALPHA-1 ANTITRYPSIN MECHANISM OF ACTION

Committed to Alpha-1 Patients

Supporting prevention of CMV disease after solid organ transplantation

MORETHERAPEUTICFOCUSAREAS

MORE
THERAPEUTIC
FOCUS
AREAS